Browse by category

A study by researchers from the University of California San Diego has revealed compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking GLP-1 medications were less than half as likely to die within five years, compared to those who weren't on the drugs (15.5% versus 37

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

The FDA has cleared Veru’s Investigational New Drug (IND) application for its Phase 2b clinical study to evaluate enobosarm, an oral...